Rapport Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023
Revenue	20	-	-	-
Gross Profit	20	-	-	-
Selling, General & Admin	34.27	30.31	22.12	8.18
Research & Development	107.93	94.79	60.94	28
Total Operating Expenses	142.21	125.1	83.06	36.18
Operating Income	-122.21	-125.1	-83.06	-36.18
Interest Income	14.93	13.62	12.14	2.53
Other Non-Operating Income (Expense)	-	-	-7.39	-1.12
Total Non-Operating Income (Expense)	14.93	13.62	4.75	1.4
Pretax Income	-107.28	-111.48	-78.31	-34.78
Provision for Income Taxes	-	-	-	0.01
Net Income	-107.28	-111.48	-78.31	-34.79
Net Income to Common	-107.28	-111.48	-78.31	-34.79
Shares Outstanding (Basic)	42	39	21	2
Shares Outstanding (Diluted)	42	39	21	2
Shares Change (YoY)	44.65%	87.74%	1277.26%	-
EPS (Basic)	-2.60	-2.86	-3.78	-23.10
EPS (Diluted)	-2.60	-2.86	-3.78	-23.10
Shares Outstanding	47.81	47.77	36.58	4.17
Free Cash Flow	-80.71	-88.09	-67.23	-28.82
Free Cash Flow Per Share	-1.93	-2.26	-3.24	-19.14
Gross Margin	100.00%	-	-	-
Operating Margin	-611.03%	-	-	-
Profit Margin	-536.38%	-	-	-
FCF Margin	-403.54%	-	-	-
EBITDA	-121.21	-124.08	-82.22	-36.07
EBITDA Margin	-606.03%	-	-	-
EBIT	-122.21	-125.1	-83.06	-36.18
EBIT Margin	-611.03%	-	-	-
Effective Tax Rate	-	0.00%	0.00%	-0.03%

SEC Filings: 10-K · 10-Q